Investigation Report on China’s Doxorubicin Market 2021-2025

$2,600$3,900

In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020.

Clear

Description

Doxorubicin belongs to the anthracycline class (Anthracycline) antibiotics, which can inhibit the synthesis of RNA and DNA. It has a strong inhibitory effect on RNA and has a broad anti-tumor spectrum. It has an effect on a variety of tumors. Doxorubicin was developed by Alza Corporation of the United States. According to CRI’s market research, as of the end of 2020, the original Doxorubicin drug has not been listed in China, but many companies have obtained approval for the listing of generic drugs in China and have been included in the China National Medical Insurance Category A catalog. By 2020, there were 8 manufacturers in the Chinese Doxorubicin market, of which CSPC Ouyi Pharmaceutical Co., Ltd. was the main manufacturer.

According to CRI’s market research, the sales value of Doxorubicin in the Chinese market has increased year by year from 2016 to 2020. Especially, the sales of Doxorubicin in the Chinese market reached CNY 855 million in 2019, a year-on-year increase of 69.75%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020. The CAGR of Doxorubicin’s sales value in the Chinese market is 38.60% from 2016 to 2020.

CRI expects that with the increase of cancer patients in 2021-2025, the sales volume of Doxorubicin in the Chinese market will increase steadily. Doxorubicin liposome injection has the advantages of targeting, sustained release, and reduced toxicity. Based on these advantages, the sales volume and sales of Doxorubicin liposome injection will continue to increase. In addition, the alleviation of the COVID-19 epidemic will also cause the sales of Doxorubicin to show a recovery growth.

Topics Covered:
-The impact of COVID-19 on China’s Doxorubicin market
– Sales value of China’s Doxorubicin 2016-2020
– Competitive landscape of China’s Doxorubicin market
– Prices of Doxorubicin in China
– Prices of Doxorubicin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Doxorubicin market
– Prospect of China’s Doxorubicin market from 2021 to 2025

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Doxorubicin
1.1 Indications for Doxorubicin
1.2 Development of Doxorubicin in China
1.3 Governmental Approval of Doxorubicin in China
1.4 The Impact of COVID-19 on Doxorubicin sales in China

2 Sales of Doxorubicin in China, 2016-2020
2.1 Sales Value of Doxorubicin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Doxorubicin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Doxorubicin by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Liposome Injection

3 Analysis of Major Doxorubicin Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Doxorubicin Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 CSPC Ouyi Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Duomeisu (CSPC Ouyi Pharmaceutical Co., Ltd.’s Doxorubicin) in China
3.3 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Libaoduo (Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.’s Doxorubicin) in China
3.4 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Lixing (Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.’s Doxorubicin) in China
3.5 Shenzhen Main Luck Pharmaceuticals Inc.
3.5.1 Enterprise Profile
3.5.2 Sales of Shenzhen Main Luck Pharmaceuticals Inc.’s Doxorubicin in China
3.6 Shanxi Powerdone Pharmaceutics Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Shanxi Powerdone Pharmaceutics Co., Ltd.’s Doxorubicin in China

4 Prices of Doxorubicin for Different Manufacturers in China, 2020-2021
4.1 CSPC Ouyi Pharmaceutical Co., Ltd. (Duomeisu)
4.2 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd. (Libaoduo)
4.3 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. (Lixing)
4.4 Shenzhen Main Luck Pharmaceuticals Inc.
4.5 Shanxi Powerdone Pharmaceutics Co., Ltd.

5 Prospect of Chinese Doxorubicin Market, 2021-2025
5.1 Influential Factors of Chinese Doxorubicin Market Development
5.1.1 The Impact of COVID-19 on Chinese Doxorubicin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Doxorubicin Injection Registration in China
Chart Patent Information About Doxorubicin Liposome Injection Registration in China
Chart Sales Value of Doxorubicin Injection over the World
Chart Sales Value of Doxorubicin Liposome Injection over the World
Chart Sales Value of Doxorubicin Injection in China, 2016-2020
Chart Sales Value of Doxorubicin Liposome Injection in China, 2016-2020
Chart Sales Value of Doxorubicin Injection in China by Region, 2016-2020
Chart Sales Value of Doxorubicin Liposome Injection in China by Region, 2016-2020
Chart Sales Volume of Doxorubicin Injection in China, 2016-2020
Chart Sales Volume of Doxorubicin Liposome Injection in China, 2016-2020
Chart Sales Volume of Doxorubicin Injection in China by Region, 2016-2020
Chart Sales Volume of Doxorubicin Liposome Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Doxorubicin Injection Manufacturers in China, 2016-2020
Chart Market Share by Sales Value of Top Doxorubicin Liposome Injection Manufacturers in China, 2016-2020
Chart Sales Value and Volume of Duomeisu in China, 2016-2020
Chart Sales Value and Volume of Libaoduo in China, 2016-2020
Chart Sales Value and Volume of Lixing in China, 2016-2020
Chart Sales Value and Volume of Shenzhen Main Luck Pharmaceuticals Inc.’s Doxorubicin in China, 2016-2020
Chart Sales Value and Volume of Shanxi Powerdone Pharmaceutics Co., Ltd.’s Doxorubicin in China, 2016-2020
Chart Referential Prices of Duomeisu in China by Region, 2020-2021
Chart Referential Prices of Libaoduo in China by Region, 2020-2021
Chart Referential Prices of Lixing in China by Region, 2020-2021
Chart Referential Prices of Shenzhen Main Luck Pharmaceuticals Inc.’s Doxorubicin in China by Region, 2020-2021
Chart Referential Prices of Shanxi Powerdone Pharmaceutics Co., Ltd.’s Doxorubicin in China by Region, 2020-2021
Chart Forecast on Sales Value of Doxorubicin Injection in China, 2021-2025
Chart Forecast on Sales Value of Doxorubicin Liposome Injection in China, 2021-2025
Chart Forecast on Sales Volume of Doxorubicin Injection in China, 2021-2025
Chart Forecast on Sales Volume of Doxorubicin Liposome Injection in China, 2021-2025